

Protein Formulation and Delivery Second Edition

Edited by

Eugene J. McNally

*Gala Biotech, a Catalent Pharma Solutions Company
Middleton, Wisconsin, USA*

Jayne E. Hastedt

*ALZA Corporation
Mountain View, California, USA*

informa
healthcare

New York London

Informa Healthcare USA, Inc.
52 Vanderbilt Avenue
New York, NY 10017

© 2008 by Informa Healthcare USA, Inc.
Informa Healthcare is an Informa business

No claim to original U.S. Government works
Printed in the United States of America on acid-free paper
10 9 8 7 6 5 4 3 2 1

International Standard Book Number-10: 0-8493-7949-0 (Hardcover)
International Standard Book Number-13: 978-0-8493-7949-9 (Hardcover)

This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequence of their use.

No part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access www.copyright.com (<http://www.copyright.com/>) or contact the Copyright Clearance Center, Inc. (CCC) 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

Library of Congress Cataloging-in-Publication Data

Protein formulation and delivery / edited by Eugene J. McNally, Jayne E. Hastedt. -- 2nd ed.
p. ; cm. -- (Drugs and the pharmaceutical sciences ; 175)
Includes bibliographical references and index.
ISBN-13: 978-0-8493-7949-9 (hardcover : alk. paper)
ISBN-10: 0-8493-7949-0 (hardcover : alk. paper)
1. Protein drugs--Dosage forms. I. McNally, Eugene J., 1961- II. Hastedt, Jayne E.
III. Series: Drugs and the pharmaceutical sciences ; v.175.
[DNLN: 1. Protein Conformation. 2. Drug Delivery Systems. 3. Drug Design.
4. Drug Stability. 5. Proteins--administration & dosage. W1 DR893B v.175 2007
/ QU 55.9 P9667 2007]

RS431.P75P77 2007
615'.19--dc22

2007023435

Visit the Informa Web site at
www.informa.com

and the Informa Healthcare Web site at
www.informahealthcare.com

Chemical Considerations in Protein and Peptide Stability

Paul M. Bummer

University of Kentucky, Lexington, Kentucky, U.S.A.

DEAMIDATION

Introduction

The deamidation reactions of asparagine (Asn) and glutamine (Gln) side-chains are among the most widely studied nonenzymatic covalent modifications to proteins and peptides (1–7). Considerable research efforts have been extended to elucidate the details of the deamidation reaction in both in vitro and in vivo systems, and a number of well-written, in-depth reviews are available (1–5,8,9). This work touches only on some of the highlights of the reaction and on the roles played by pH, temperature, buffer, and other formulation components. Possible deamidation-associated changes in the protein structure and state of aggregation also are examined. The emphasis is on Asn deamidation, since Gln is significantly less reactive.

Reaction Mechanism

The primary reaction mechanism for the deamidation of Asn in water-accessible regions of peptides and proteins at basic or neutral conditions is shown in Figure 1. For the present, discussion is confined to the intramolecular mechanism, uncomplicated by adjacent amino acids at other points in the primary sequence. Under alkaline conditions, the key step in the reaction is the formation of a deprotonated amide nitrogen, which carries out the rate-determining nucleophilic attack on the side-chain carbonyl, resulting in a tetrahedral intermediate and finally the formation of the five-member succinimide ring. For such a reaction, the leaving group must be




Figure 1 Proposed reaction mechanism for deamidation of asparaginyl residue. Note the formation of the succinimidyl intermediate and the two possible final products.


easily protonated, and in this case, it is responsible for the characteristic formation of ammonia (NH_3). The succinimide ring intermediate is subject to hydrolysis, resulting in either the corresponding aspartic acid or the isoaspartic acid (β -aspartate). Often, the ratio of the products is 3:1, isoaspartate to aspartate (10–12). In the case of acid catalysis ($\text{pH} < 3$), a tetrahedral intermediate is also formed, but breaks down with the loss of NH_3 without going through the succinimide (13–17). The reaction also appears to be sensitive to racemization at the α -carbon, resulting in mixtures of *D*- and *L*-isomers (10,13–15). The rate of degradation of the parent peptide in aqueous media often follows pseudo-first-order kinetics (16,17).

A number of other alternative reactions are possible. The most prevalent reaction appears to be a nucleophilic attack of the Asn side-chain amide nitrogen on the peptide carbonyl, resulting in main-chain cleavage (10,16,18). This reaction (Fig. 2) is slower than that of cyclic imide formation and is most frequently observed when Asn is followed by proline, a residue incapable of forming an ionized peptide-bond nitrogen.

pH Dependence

Under conditions of strong acid (pH 1–2), deamidation by direct hydrolysis of the amide side-chain becomes more favorable than formation of cyclic imide (16,19). Under these extreme conditions, the reaction is often complicated by main-chain cleavage and denaturation. Deamidation by this mechanism is not likely to produce isoaspartate or significant racemization (16).

Under more moderate conditions, the effect of pH is the result of two opposing reactions: (i) deprotonation of the peptide-bond nitrogen, promoting



R1 = Amino end of protein

R2 = Carboxyl end of protein

Figure 2 Proposed reaction mechanism for main-chain cleavage by asparaginyl residues.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.